Abstract
OBJECTIVE: The unique pharmacokinetics of bisphosphonates (BPs) in conjunction with their use by an increasing number of women at reproductive age has raised serious concerns about their safety during pregnancy and lactation. Bisphosphonates cross the placenta. Animal studies have shown adverse effects on both the fetus and the mother, mostly at doses much higher than those commonly used in humans. Protracted parturition, maternal mortality, embryolethality, severe general underdevelopment and marked skeletal retardation of the fetuses (increased amount of diaphyseal bone trabeculae, decreased diaphyseal length), small fetal weight and abnormal tooth growth have been observed. DESIGN: We conducted a thorough research of the literature in order to identify human studies concerning this issue. RESULTS: We identified a total of 78 cases involving fetuses whose mothers had been exposed to BPs before conception or during pregnancy, along with 7 cases of BPs exposure prior to or during lactation. The vast majority of mothers and infants did not demonstrate serious adverse effects. However, there were cases of shortened gestational age, low neonatal birth weight and transient hypocalcaemia of the newborns, while the very few reported cases of spontaneous abortions and congenital anomalies probably resulted from maternal underlying diseases and concomitant medication. CONCLUSION: The administration of bisphosphonates in pregnancy should be assessed in view of their potential hazardous effects on both mother and fetus. In cases of absolute or relative indications of BPs prior to pregnancy, close observation of the mother and the infant, especially during the first two weeks of life, is imperative for the successful outcome of pregnancy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Top 200 brand-name drugs by units in 2006.” https://doi.org/www.drug-topics.com/drugtopics/Pharmacy+Facts+And+Figures/Top-200-brand-name-drugs-by-units-in-2006.
Drake MT, Clarke BL, Khosla S, 2008 Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83: 1032–1045.
Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A, 1999 Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60: 68–73.
Minsker DH, Manson JM, Peter CP, 1993 Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 121: 217–223.
Graepel P, Bentley P, Fritz H, Miyamoto M, Slater SR, 1992 Reproduction toxicity studies with pamidronate. Arzneimittelforschung 42: 654–667.
Ornoy A, Wajnberg R, Diav-Citrin O, 2006 The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 22: 578–579.
Levy S, Fayez I, Taguchi N, et al, 2009 Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44: 428–430.
Losada I, Sartori L, Di Gianantonio E, Zen M, Clementi M, Doria A, 2010 Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age? Autoimmun Rev 9: 547–552.
Chan B, Zacharin M, 2006 Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 91: 2017–2020.
Munns CF, Rauch F, Ward L, Glorieux FH, 2004 Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19: 1742–1745.
Hassen-Zrour S, Korbaa W, Bejia I, Saidani Z, Bergaoui N, 2010 Maternal and fetal outcome after long-term bisphosphonate exposure before conception. Osteoporos Int 21: 709–710.
Harsch IA, Hubner RH, Hahn EG, Hensen J, 2001 [Osteoporosis and multiple pregnancy--a case report with positive outcome]. Med Klin (Munich) 96: 402–407.
Athimulam S, Chan P, Baker M, Nauta M, Yoong W, 2007 The effect of pregnancy on pre-existing osteopenia: a case report. Arch Gynecol Obstet 276: 175–177.
Vujasinovic-Stupar N, Pejnovic N, Markovic L, Zlatanovic M, 2011 Pregnancy-associated spinal osteoporosis treated with bisphosphonates: long-term follow-up of maternal and infants outcome. Rheumatol Int, in press.
Cabar FR, Nomura RM, Zugaib M, 2007 Maternal and fetal outcome of pamidronate treatment before conception: a case report. Clin Exp Rheumatol 25: 344–345.
Rutgers-Verhage AR, deVries TW, Torringa MJ, 2003 No effects of bisphosphonates on the human fetus. Birth Defects Res A Clin Mol Teratol 67: 203–204.
Mastaglia SR, Watman NP, Oliveri B, 2010 Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health. Osteoporos Int 21: 1959–1962.
Biswas PN, Wilton LV, Shakir SA, 2003 Pharmacovigilance study of alendronate in England. Osteoporos Int 14: 507–514.
Dunlop DJ, Soukop M, McEwan HP, 1990 Antenatal administration of aminopropylidene diphosphonate. Ann Rheum Dis 49: 955.
Illidge TM, Hussey M, Godden CW, 1996 Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol (R Coll Radiol) 8: 257–258.
Andreadis C, Charalampidou M, Diamantopoulos N, Chouchos N, Mouratidou D, 2004 Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer. Gynecol Oncol 95: 252–255.
Culbert EC, Schfirin BS, 2006 Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions. Obstet Gynecol 108: 789–791.
Siminoski K, Fitzgerald AA, Flesch G, Gross MS, 2000 Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res 15: 2052–2055.
Hedrick WR, DiSimone RN, Wolf BH, Langer A, 1998 Absorbed dose to the fetus during bone scintigraphy. Radiology 168: 245–248.
Palestro CJ, Malat J, Collica CJ, Richman AH, 1986 Incidental diagnosis of pregnancy on bone and gallium scintigraphy. J Nucl Med 27: 370–372.
McKenzie AF, Budd RS, Yang C, Shapiro B, Hicks RJ, 1994 Technetium-99m-methylene diphosphonate uptake in the fetal skeleton at 30 weeks gestation. J Nucl Med 35: 1338–1341.
Black AJ, Topping J, Durham B, Farquharson RG, Fraser WD, 2000 A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J Bone Miner Res 15: 557–563.
Kovacs C, 2006 Skeletal physiology: fetus and neonate. Primer on the metabolic bone diseases and disorders of mineral metabolism, pp; 50–55.
Nancollas GH, Tang R, Phipps RJ, et al, 2006 Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38: 617–627.
Dunford JE, Thompson K, Coxon FP, et al, 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235–242.
Lin JH, 1996 Bisphosphonates: a review of their pharmacokinetic properties. Bone 18: 75–85.
Cremers SC, Pillai G, Papapoulos SE, 2005 Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44: 551–570.
Kimmel DB, 2007 Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86: 1022–1033.
Khan SA, Kanis JA, Vasikaran S, et al, 1997 Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12: 1700–1707.
Papapoulos SE, Cremers SC, 2007 Prolonged bisphosphonate release after treatment in children. N Engl J Med 356: 1075–1076.
Peris P, Torra M, Olivares V, et al, 2011 Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone 49: 706–709.
Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C, 2003 Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33: 301–307.
Landman JO, Hamdy NA, Pauwels EK, Papapoulos SE, 1995 Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J Clin Endocrinol Metab 80: 3465–3468.
Bone HG, Hosking D, Devogelaer JP, et al, 2004 Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189–1199.
Black DM, Schwartz AV, Ensrud KE, et al, 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927–2938.
Watts NB, Chines A, Olszynski WP, et al, 2008 Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 19: 365–672.
Guyton A 1992. Medical Physiology, Paschalidis eds, Athens; pp, 1205–1207.
Reid DM, Devogelaer JP, Saag K, et al, 2009 Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373: 1253–1263.
Ott SM, 2004 Effects of bisphosphonates during pregnancy. https://doi.org/courses.washington.edu/bonephys/oppregnancy.html#Bis. 2010 November, 26.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ioannis, S.P., Chrysoula, L.G., Aikaterini, K. et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones 10, 280–291 (2011). https://doi.org/10.14310/horm.2002.1319
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1319